Financial Performance - In Q3 2025, the company reported revenue of $15.6 million, gross profit of $9.5 million, and a gross margin of 60.8%[160] - The company's net income for the quarter was $3.5 million, influenced by a $1.3 million increase in revenue from solar power project development and a $3.0 million increase from electricity generation[160] - The gross margin increased to 60.8% in Q3 2025 from 43.8% in Q3 2024, primarily due to a shift towards higher-margin electricity generation[178] - Net revenue increased from $12.9 million in Q3 2024 to $15.6 million in Q3 2025, primarily due to a $3.0 million increase in electricity generation revenue and a $1.3 million increase in solar power project development revenue[199] - Gross profit for Q3 2025 was $9.5 million, up from $5.6 million in Q3 2024, with a gross margin increase to 60.8% from 43.8%[201] - Net income for Q3 2025 was $3.5 million, compared to $5.7 million in Q3 2024, with a net loss attributed to Emeren Group Ltd of $0.3 million[199] - Net income decreased from $5.7 million in Q3 2024 to $3.5 million in Q3 2025, primarily due to a $5.1 million drop in unrealized foreign exchange gains and a $1.0 million increase in income tax expense[210] Revenue Sources - The Independent Power Producer (IPP) business accounted for over 79.2% of total revenue and 90.0% of total gross profit for the quarter[161] - Net revenue from China was $7.3 million in Q3 2025, compared to $5.3 million in Q3 2024[176] - The company expects revenue from solar and storage power projects to increase in line with business growth[176] - Revenue from EPC services decreased significantly, driven by the company's strategy to prioritize other revenue streams since 2024[199] Project Development - As of September 30, 2025, the company had a project pipeline of 5,782 MW in solar development projects, with 2,668 MW in advanced stage and 3,114 MW in early stage[167] - The company owned and operated IPP assets comprising 294 MW of solar PV projects and 74 MWh of storage as of September 30, 2025[171] - The company experienced delays in project milestones and completions, particularly in the U.S. and Europe, impacting revenue recognition[199] Expenses and Cash Flow - General and administrative expenses decreased from $4.0 million in Q3 2024 to $1.4 million in Q3 2025, primarily due to a $3.6 million credit loss reversal[203] - Total operating expenses for Q3 2025 were $2.7 million, down from $3.5 million in Q3 2024[196] - Cost of revenue decreased from $7.2 million in Q3 2024 to $6.1 million in Q3 2025, and from $38.2 million in the nine months ended September 30, 2024 to $17.3 million in the same period of 2025[200] - Other operating expenses increased from $1.4 million in the nine months ended September 30, 2024 to $7.5 million in the same period of 2025, mainly due to higher write-offs and project cancellations[204] - Positive operating cash flow of $34.5 million was generated for the nine months ended September 30, 2025, compared to a cash outflow of $14.6 million in the same period of 2024[211] - Net cash provided by operating activities increased by $49.1 million compared to the prior period, driven by non-cash adjustments and higher cash inflows from project assets[233] Mergers and Agreements - The company entered into a merger agreement with Shurya Vitra Ltd. and Emeren Holdings Ltd., with each ordinary share converting to $0.20 in cash[162] - The company entered into a merger agreement on June 18, 2025, with a cash consideration of $0.20 per ordinary share and $2.00 per American Depositary Share[215] Financial Position - Total current assets were $178.4 million as of September 30, 2025, with cash and cash equivalents amounting to $86.5 million[213] - As of September 30, 2025, the outstanding balance under a facility agreement with a local lender in Hungary was $24.5 million, with $1.7 million classified as current[230] Interest and Foreign Exchange - Interest income increased from $0.2 million in Q3 2024 to $0.3 million in Q3 2025, while interest expenses rose from $0.7 million to $1.6 million during the same period[207] - Unrealized foreign exchange gains were $4.6 million in Q3 2024, turning into a loss of $0.4 million in Q3 2025; for the nine months, gains increased from $0.5 million to $14.2 million[208] Future Expectations - The company expects to finance future transactions with a combination of cash, long-term indebtedness, and share issuance[212] - Cash flows from investing activities decreased by $5.5 million, mainly due to reduced purchases of property, plant, and equipment[235]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Delaware | 87-4227079 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________to _______________. Commission ...

Financial Performance - Entera Bio reported a net loss of $3.2 million, or $0.07 per ordinary share, for Q3 2025, compared to a net loss of $3.0 million, or $0.08 per ordinary share, in Q3 2024[8]. - Total operating expenses for Q3 2025 were $3.3 million, compared to $3.0 million in Q3 2024[9]. - Entera Bio's total assets increased to $17.4 million as of September 30, 2025, from $9.4 million as of December 31, 2024[14]. Cash Position - Cash and cash equivalents were $16.6 million as of September 30, 2025, including $8.0 million in restricted cash for the OPKO collaboration[7]. Research and Development - Research and development expenses increased to $1.6 million in Q3 2025 from $1.5 million in Q3 2024, reflecting ongoing regulatory and Phase 3 preparation activities for EB613[8]. - The FDA agreed to use bone mineral density (BMD) as the primary endpoint for the Phase 3 study of EB613, which is designed to support a New Drug Application (NDA)[3]. - Phase 2 data for EB613 showed significant increases in trabecular and cortical bone indices after six months of treatment, comparable to injectable therapies[3]. - The company plans to initiate a Phase 1 trial of Next-Gen EB613 in late 2025, with preclinical data supporting its pharmacokinetic profile[3]. Product Development - The dual GLP-1/glucagon OXM tablet program demonstrated plasma levels consistent with the highest subcutaneous dose of Wegovy, indicating potential for obesity treatment[5]. - The oral GLP-2 program for short bowel syndrome showed a plasma half-life of approximately 15 hours, an 18-fold improvement over the current approved therapy[4].

Revenue Performance - Revenue increased by $1.7 million, or 9%, from $19.0 million for the three months ended September 30, 2024, to $20.7 million for the same period in 2025[117]. - Revenue for the nine months ended September 30, 2025, was $59.4 million, an increase of $7.8 million, or 15%, from $51.7 million for the same period in 2024[117]. - Revenue increased by $1.7 million, or 9%, to $20.7 million for the three months ended September 30, 2025, driven by new customers and growing international sales[140]. - Revenue increased by $7.8 million, or 15%, to $59.4 million for the nine months ended September 30, 2025, compared to $51.7 million for the same period in 2024, driven by new customers and growing international sales[155]. Net Loss and Financial Position - The net loss decreased by $1.8 million, or 17%, from $10.4 million for the three months ended September 30, 2024, to $8.6 million for the same period in 2025[117]. - The company has an accumulated deficit of $388.5 million as of September 30, 2025, and expects to incur losses for the foreseeable future[119]. - Net loss for the nine months ended September 30, 2025, was $29.8 million, compared to a net loss of $28.6 million for the same period in 2024, reflecting a 4% increase in loss[167]. - As of September 30, 2025, cash and cash equivalents were $29.7 million, down from $52.7 million as of December 31, 2024[168]. - Cash used in operating activities was $23.3 million for the nine months ended September 30, 2025, an improvement from $34.1 million used in the same period in 2024[173]. Market Opportunity - The annual U.S. total addressable market opportunity for OviTex products is estimated to be approximately $1.8 billion[104]. - The annual U.S. current addressable market opportunity for OviTex PRS products is estimated to be approximately $800 million[109]. Product Development and Sales - The OviTex portfolio includes multiple configurations for various surgical procedures, with new product launches in 2023 and 2024 targeting specific hernia repair needs[105]. - Unit sales volume of OviTex increased by 22% to 5,795 units for the three months ended September 30, 2025, compared to 4,767 units in the same period of 2024[140]. - The company is focusing on research and development for new product variations and enhancements to extend the shelf life of existing products[116]. Expenses and Cost Management - Cost of revenue increased by $0.6 million, or 10%, to $6.6 million for the three months ended September 30, 2025, primarily due to higher product purchases[141]. - Gross profit increased by $1.1 million, or 9%, to $14.0 million for the three months ended September 30, 2025, attributed to increased unit sales and new customers[143]. - Sales and marketing expenses decreased by $1.2 million, or 8%, to $15.2 million for the three months ended September 30, 2025, due to lower compensation and benefits[146]. - General and administrative expenses increased by $0.3 million, or 7%, to $3.9 million for the three months ended September 30, 2025, primarily due to higher compensation and professional fees[147]. - Research and development expenses increased by $0.3 million, or 14%, to $2.3 million for the three months ended September 30, 2025, mainly due to higher study and development costs[148]. - Cost of revenue (excluding amortization of intangible assets) rose by $2.4 million, or 15%, to $18.5 million for the nine months ended September 30, 2025, primarily due to increased product purchases to support higher unit sales[156]. - Gross profit increased by $5.3 million, or 15%, to $40.6 million for the nine months ended September 30, 2025, attributed to higher unit sales and new customer additions[158]. - Sales and marketing expenses decreased by $2.0 million, or 4%, to $48.7 million for the nine months ended September 30, 2025, mainly due to lower compensation and benefits[161]. - General and administrative expenses increased by $0.8 million, or 7%, to $11.9 million for the nine months ended September 30, 2025, driven by higher professional fees and compensation[162]. - Research and development expenses rose by $0.3 million, or 5%, to $7.1 million for the nine months ended September 30, 2025, due to increased study costs[163]. Debt and Financing - The MidCap term loan matures on May 1, 2027, with an interest rate of 6.25% plus the greater of one-month Term SOFR or 1.0%[183]. - A debt refinancing transaction secured up to $70.0 million from Perceptive Advisors, with an initial loan of $60.0 million and an additional $10.0 million available upon meeting certain conditions[186]. - The new credit facility bears interest at a rate of 7.85% plus the greater of one-month Term SOFR or 4.25%, maturing on November 14, 2030[186]. - A 1% increase in interest rates would have resulted in a $0.3 million increase in interest expense for the nine months ended September 30, 2025[191]. - The company has made 36 monthly interest payments on the MidCap term loan since June 2022, with an extension of these payments elected in May 2025[183]. - The MidCap term loan has a prepayment fee of 1.0% and an exit fee of 5% at maturity or prepayment[184]. - As of September 30, 2025, there were no significant changes to the company's commitments and future minimum contractual obligations[185]. Risk Factors - The company is currently assessing the impact of the One Big Beautiful, Bill Act ("OBBBA") on its consolidated financial statements[152]. - The company does not currently have any material exposure to foreign currency fluctuations and does not engage in hedging activities[193]. - Inflationary factors may adversely affect operating results, although the company does not believe inflation has had a material impact to date[192]. - The company has established a redundant account at a high-credit-quality financial institution to mitigate liquidity risk following the events related to Silicon Valley Bank in 2023[189].

Revenue and Income - Total revenues for the three months ended September 30, 2025, were $7,450, with $5,275 from subscription services and $2,175 from installation fees[136]. - The company recognized total revenues of $98,175 for the nine months ended September 30, 2025, with $89,000 from consulting services[145]. - For the nine months ended September 30, 2025, total revenue was $8,281,262, representing a 157% increase compared to $3,225,920 in the same period of 2024[148]. - Other income rose to $83,454, a 183% increase from $29,523, mainly from payroll tax refunds and state tax credits[152]. Expenses - Operating expenses for the same period increased by 100% to $1,657,731, driven by a 73% rise in general and administrative expenses to $1,370,347[138]. - General and administrative expenses for the nine months ended September 30, 2025, were $7,551,884, reflecting a 215% increase from $2,395,881 in the prior year[147]. - General and administrative expenses increased by $5,156,003 to $6,156,003, primarily due to a $4,359,704 rise in salaries and benefits, including $1,866,531 in one-time success bonuses[149]. - Research and development expenses rose significantly to $179,854, a 2,165% increase compared to the prior year[140]. - Research and Development expenses were $564,585, an increase of $15,706 from the prior year, driven by higher independent contractor spend[150]. - Marketing expenses decreased by $116,367 to $164,793, attributed to one-time television advertising costs in the prior year[151]. Cash Flow and Financing - Net cash used in operating activities was $5,048,431, an increase of $3,088,984 compared to $1,959,447 in the same period of 2024[161]. - Net cash provided by financing activities was $7,772,302, including $7,530,000 from convertible debt issuance[166]. - As of September 30, 2025, cash on hand was $816,715, and short-term investments totaled $1,918,995, providing approximately three and a half months of runway[156]. Shareholder Actions - The company has initiated a share repurchase program of up to $10 million from September 8, 2025, through March 31, 2026[132]. - As of September 30, 2025, the company had 34,213,387 shares outstanding, with potential dilution scenarios indicating a 22% increase if maximum Streeterville shares are issued[130][131]. Employee and Operational Growth - The company had 33 full-time salaried employees as of September 30, 2025, compared to 8 in the same period last year, reflecting significant hiring in product development and marketing[159]. Future Plans and Developments - The company installed third-generation Arrive Points ("AP3" units) in Q4 of 2024, which began revenue operation in 2025[124]. - The company plans to leverage machine learning and artificial intelligence for data monetization and insights generation[125][126]. - The ALM Marketplace is being developed to optimize access schedules and space availability for the Arrive Points network[127]. Net Loss - The company reported a net loss of $8,904,672 for the nine months ended September 30, 2025, offset by non-cash items including stock-based compensation of $3,134,655[162].

U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 001-37370 MY SIZE, INC. (Exact name of registrant as specified in its charter) Delaware 51-0394637 (State or other jurisdiction of incorporation ...

Financial Performance - For the three months ended September 30, 2025, the company's net loss was $5.5 million, a decrease from $8.2 million in the same period of the prior year [148]. - General, selling, and administrative expenses for the nine months ended September 30, 2025, increased by 25% to $19.2 million compared to $15.4 million in 2024, primarily due to higher stock-based compensation and legal costs [149]. - Research and development expenses for the three months ended September 30, 2025, decreased by 10% to $4.7 million from $5.3 million in 2024, mainly due to reduced outside services and prototype tooling costs [144]. - The company experienced a 50% increase in share-based compensation expenses for the nine months ended September 30, 2025, totaling $12.4 million compared to $8.3 million in 2024 [149]. - Research and Development expenses increased by 18% to $13.8 million for the nine months ended September 30, 2025, compared to $11.7 million in the same period of 2024, primarily due to higher stock-based compensation [153][154]. - Other income for the three months ended September 30, 2025, was $2.5 million, significantly up from $0.1 million in the same period of 2024, primarily due to matching grant funds from the California Energy Commission [147]. - Other income rose significantly to $4.6 million in the nine months ended September 30, 2025, from $1.1 million in the same period of 2024, largely due to $3.9 million in matching grant funds from the California Energy Commission [157]. Capital Requirements - The estimated capital required for the initial low-volume production phase is approximately $65 million, with an additional $140-$160 million needed to ramp up to a high-volume production rate of 20,000 vehicles per year [130]. - The company requires approximately $60-70 million in additional funding to advance through critical pre-production phases, including vehicle validation and low-volume manufacturing [162]. - The company secured a $75 million committed equity line of credit (ELOC) to support its capital needs, contingent upon certain conditions [125]. - The company has secured a committed equity line of credit (ELOC) of up to $75.0 million, which is subject to various conditions, to address liquidity needs [161]. Assets and Liabilities - As of September 30, 2025, the company had total assets of $34.9 million, including $12.0 million in cash and cash equivalents, with a monthly cash burn rate of approximately $1.5 to $2.0 million [158]. - Total liabilities as of September 30, 2025, were $7.7 million, including $1.2 million in accrued liabilities and $4.1 million in unearned reservation fees [168]. - During the nine months ended September 30, 2025, the company issued 278,417 shares of Class B Common Stock for total cash proceeds of $11.2 million at a weighted-average price of $40.12 per share [169]. Legal and Regulatory Issues - The company is currently involved in litigation with Zaptera, which asserts claims for design patent infringement and misappropriation of trade secrets [174][175]. - The company is cooperating with an ongoing SEC investigation related to its securities offerings and vehicle production, with no assurance on the outcome [176][177]. Production and Reservations - As of September 30, 2025, Aptera Motors had approximately 49,000 reservation holders but had not delivered any products or recognized any revenue from vehicle sales [126]. - The company is facing challenges in securing sufficient capital, which is critical for commencing production and achieving its business objectives [133]. - The company anticipates receiving approximately $3.5 million in grant disbursements from the California Energy Commission in 2025, contingent upon meeting specific project milestones [164].

IPO and Offering Details - The company completed its Initial Public Offering (IPO) on August 8, 2024, raising gross proceeds of $253 million from the sale of 25,300,000 Units[132]. - The company incurred offering expenses of approximately $1,173,390 and underwriting commissions of $4,400,000 during the IPO[144]. - The underwriters are entitled to a deferred underwriting commission of $12,045,000 upon the completion of the initial Business Combination[156]. Financial Performance - The company generated a net income of $2,358,611 for the three months ended September 30, 2025, compared to $1,321,694 for the same period in 2024, primarily from $2,763,576 in income from investments held in the Trust Account[137]. - For the nine months ended September 30, 2025, the company reported a net income of $7,283,753, significantly up from $1,218,846 in the same period in 2024, with $8,195,502 from investments held in the Trust Account[138]. Trust Account and Liquidity - As of September 30, 2025, the Trust Account held $267,284,310 in a money market fund, an increase from $259,099,778 held in U.S. Treasury bills as of December 31, 2024[145]. - The company intends to use substantially all funds in the Trust Account to complete its initial business combination, with potential withdrawals for income taxes[147]. - As of September 30, 2025, the Company had a cash balance of $252,350 held outside the trust account[148]. - The Company expects primary liquidity requirements to include approximately $1,425,000 for general working capital and other expenses[151]. Business Operations and Future Plans - The company has not engaged in any operations or generated revenues to date, with activities limited to organizational tasks and preparations for the IPO and initial business combination[136]. - The company has entered into a Business Combination Agreement with Veraxa Biotech AG, outlining a two-step transaction for the merger[134][135]. - The company expects to incur increased expenses as a result of being a public company, including legal and compliance costs[136]. - The Company does not anticipate needing to raise additional funds prior to the initial Business Combination, but may require additional financing if costs exceed estimates[153]. Debt and Financial Obligations - The Company does not have any long-term debt or significant contractual obligations, except for an agreement to pay $10,000 per month for office space and support services[155]. - The Company has not borrowed any amounts under its promissory note with the sponsor as of September 30, 2025[142]. - Up to $1,500,000 of loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender[150]. - The Company has no off-balance sheet arrangements or commitments as of September 30, 2025[154]. Financial Reporting and Valuation - The preparation of financial statements involves significant judgment and estimates, which could lead to material differences from actual results[157]. - The Company's warrants were recorded at fair value using a Monte Carlo simulation model, with key assumptions affecting the valuation[158]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[159].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42211 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Former name, former address and former fiscal year, if changed since last report) Securities r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41153 ALPHA STAR ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jurisdict ...